[HTML][HTML] Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin …
A Iskenderian, N Liu, Q Deng, Y Huang, C Shen… - Skeletal Muscle, 2018 - Springer
Background Myostatin antagonists are being developed as therapies for Duchenne
muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered …
muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered …
Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone.
A Iskenderian, N Liu, Q Deng, Y Huang, C Shen… - Skeletal …, 2018 - europepmc.org
Background Myostatin antagonists are being developed as therapies for Duchenne
muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered …
muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered …
Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone.
A Iskenderian, N Liu, Q Deng, Y Huang… - Skeletal …, 2018 - search.ebscohost.com
Background: Myostatin antagonists are being developed as therapies for Duchenne
muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered …
muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered …
[引用][C] Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade …
A Iskenderian, N Liu, Q Deng, Y Huang, C Shen… - Skeletal Muscle, 2018 - cir.nii.ac.jp
Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves
dystrophic pathology in mdx mouse more than myostatin blockade alone | CiNii Research …
dystrophic pathology in mdx mouse more than myostatin blockade alone | CiNii Research …
Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone
A Iskenderian, N Liu, Q Deng, Y Huang, C Shen… - Skeletal …, 2018 - go.gale.com
Background Myostatin antagonists are being developed as therapies for Duchenne
muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered …
muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered …
[HTML][HTML] Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin …
A Iskenderian, N Liu, Q Deng… - Skeletal …, 2018 - skeletalmusclejournal.biomedcentral …
Myostatin antagonists are being developed as therapies for Duchenne muscular dystrophy
due to their strong hypertrophic effects on skeletal muscle. Engineered follistatin has the …
due to their strong hypertrophic effects on skeletal muscle. Engineered follistatin has the …
Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone
A Iskenderian, N Liu, Q Deng, Y Huang… - Skeletal …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Myostatin antagonists are being developed as therapies for Duchenne
muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered …
muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered …
Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone
A Iskenderian, N Liu, Q Deng, Y Huang… - Skeletal …, 2018 - search.proquest.com
Background Myostatin antagonists are being developed as therapies for Duchenne
muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered …
muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered …
[HTML][HTML] Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin …
A Iskenderian, N Liu, Q Deng, Y Huang, C Shen… - Skeletal …, 2018 - ncbi.nlm.nih.gov
Background Myostatin antagonists are being developed as therapies for Duchenne
muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered …
muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered …
[PDF][PDF] Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade …
A Iskenderian, N Liu, Q Deng, Y Huang, C Shen… - 2018 - skeletalmusclejournal.biomedcentral …
Background: Myostatin antagonists are being developed as therapies for Duchenne
muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered …
muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered …